Earnings summaries and quarterly performance for SelectQuote.
Executive leadership at SelectQuote.
Timothy R. Danker
Detailed
Chief Executive Officer
CEO
DA
Daniel A. Boulware
Detailed
General Counsel and Corporate Secretary
JB
Joshua B. Matthews
Detailed
President, Senior Division
RG
Robert Grant
Detailed
President
RM
Ryan M. Clement
Detailed
Chief Financial Officer
SA
Sarah Anderson
Detailed
Executive Vice President, Healthcare Pharmacy Services
SF
Stephanie Fisher
Detailed
Chief Accounting Officer
WG
William Grant III
Detailed
Chief Operating Officer
Board of directors at SelectQuote.
Research analysts who have asked questions during SelectQuote earnings calls.
Benjamin Hendrix
RBC Capital Markets
4 questions for SLQT
Also covers: ACHC, ADUS, AHCO +25 more
George Sutton
Craig-Hallum
4 questions for SLQT
Also covers: ACIW, AEYE, AGYS +26 more
PM
Patrick McCann
Noble Capital Markets
4 questions for SLQT
Also covers: BTM, CNDT, DRCT +3 more
GS
George Stottman
Craig-Hallum Capital Group LLC
1 question for SLQT
MM
Matt McCann
NOBLE Capital Markets
1 question for SLQT
MM
Michael Murray
RBC Capital Markets
1 question for SLQT
Also covers: ADUS, AHCO, AMED +7 more
Recent press releases and 8-K filings for SLQT.
SelectQuote Announces Q1 Fiscal 2026 Results
SLQT
Earnings
Revenue Acceleration/Inflection
Guidance Update
- SelectQuote reported consolidated revenue of $329 million for Q1 Fiscal 2026, representing a 13% year-over-year increase, primarily driven by strong performance in Healthcare Services.
- Consolidated Adjusted EBITDA for Q1 Fiscal 2026 was $(32) million, falling below the guided range of $(25) to $(30) million.
- The Healthcare Services segment's revenue increased 42% year-over-year to $221 million in Q1 Fiscal 2026, and the company anticipates full year revenue growth for this segment to exceed 20%.
- The Senior segment's revenue decreased to $59 million in Q1 Fiscal 2026 from $93 million in Q1 Fiscal 2025, with Adjusted EBITDA declining to $(21) million from $8 million, due to new SEP dynamics and AEP investments.
Nov 6, 2025, 1:30 PM
SelectQuote Reports Q1 2026 Results with Revenue Growth and Healthcare Services Headwinds
SLQT
Earnings
Guidance Update
Demand Weakening
- SelectQuote reported consolidated revenue of $329 million for Q1 2026, representing 13% growth over the prior year, primarily driven by the SelectRx and life insurance businesses.
- The Senior segment's revenue declined 37% to $59 million in Q1 2026, with a negative EBITDA of $21 million, due to 32% fewer policies resulting from changes in beneficiary eligibility requirements during the Special Election Period (SEP) and investments in agent hiring.
- Healthcare Services' Q1 2026 EBITDA was impacted by a change in drug reimbursement rates with a PBM partner, which is expected to create a $20 million headwind primarily in fiscal Q2, leading to an anticipated break-even adjusted EBITDA for the segment in Q2.
- Despite these near-term challenges, SelectQuote maintained its fiscal 2026 financial outlook of $1.65 billion-$1.75 billion in revenue and $120 million-$150 million in adjusted EBITDA, and expects to be operating cash flow positive for the fiscal year.
Nov 6, 2025, 1:30 PM
SelectQuote, Inc. Reports Q1 Fiscal Year 2026 Results
SLQT
Earnings
Guidance Update
Revenue Acceleration/Inflection
- SelectQuote, Inc. reported consolidated revenue of $328.8 million for the first quarter of fiscal year 2026, an increase from $292.3 million in the prior year period, with a net loss of $30.5 million, an improvement from a $44.5 million net loss in Q1 FY25.
- Consolidated Adjusted EBITDA for Q1 FY26 was $(32.1) million, compared to $(1.7) million in Q1 FY25.
- The Healthcare Services segment's revenue increased 42% to $221.4 million and Adjusted EBITDA rose 48% to $7.2 million in Q1 FY26, while the Senior segment's revenue decreased 37% to $59.0 million with an Adjusted EBITDA of $(21.0) million.
- The company reaffirmed its fiscal year 2026 financial outlook, projecting $1.65 to $1.75 billion in revenue and $120 to $150 million in Adjusted EBITDA.
Nov 6, 2025, 12:33 PM
SelectQuote, Inc. Reports First Quarter Fiscal Year 2026 Results
SLQT
Earnings
Guidance Update
Revenue Acceleration/Inflection
- SelectQuote, Inc. reported consolidated revenue of $328.8 million for the first quarter of fiscal year 2026, an increase from $292.3 million in the prior year period, alongside a net loss of $(30.5) million and Adjusted EBITDA of $(32.1) million.
- The Healthcare Services segment generated $221.4 million in revenue and $7.2 million in Adjusted EBITDA for Q1 FY2026, serving 106,914 SelectRx members as of September 30, 2025.
- The company reaffirmed its fiscal year 2026 financial outlook, expecting $1.65 to $1.75 billion in revenue and $120 to $150 million in Adjusted EBITDA.
Nov 6, 2025, 12:30 PM
SelectQuote Faces Securities Class Action and DOJ False Claims Act Complaint
SLQT
Legal Proceedings
- Faruqi & Faruqi, LLP is investigating SelectQuote (SLQT) for alleged federal securities law violations, encouraging investors who purchased securities between September 9, 2020, and May 1, 2025, to contact them.
- A federal securities class action has been filed against SelectQuote, with a October 10, 2025 deadline for investors to seek the role of lead plaintiff.
- The complaint alleges SelectQuote directed Medicare beneficiaries to plans that best compensated the company, regardless of suitability, and received illegal kickbacks.
- On May 1, 2025, the U.S. Department of Justice filed a False Claims Act complaint, alleging SelectQuote received "tens of millions of dollars" in illegal kickbacks from 2016 through at least 2021.
- Following this news, SelectQuote's stock price fell $0.61, or 19.2%, to close at $2.56 per share on May 1, 2025.
Oct 10, 2025, 11:44 PM
SelectQuote faces class action lawsuit over alleged illegal kickbacks
SLQT
Legal Proceedings
Financial Restatement
- A class action lawsuit has been filed against SelectQuote, Inc. (SLQT) by Bragar Eagel & Squire, P.C., on behalf of investors who purchased or acquired the company's securities between September 9, 2020, and May 1, 2025.
- The lawsuit follows a U.S. Department of Justice (DOJ) complaint filed on May 1, 2025, alleging SelectQuote received "tens of millions of dollars" in "illegal kickbacks" from health insurance companies from 2016 through at least 2021 for steering Medicare beneficiaries to certain plans.
- The DOJ concluded that SelectQuote made materially false claims by stating it offers "unbiased coverage comparisons" while allegedly directing beneficiaries to plans offered by insurers that paid them the most.
- On May 1, 2025, following the news of the DOJ complaint, SelectQuote's stock price fell $0.61, or 19.2%, to close at $2.56 per share.
- Investors have until October 10, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Oct 10, 2025, 2:35 PM
SelectQuote Faces Investor Lawsuit After DOJ Intervention in Medicare Sales Probe
SLQT
Legal Proceedings
Demand Weakening
- SelectQuote (SLQT) is facing a securities class-action lawsuit, Pahlkotter v. SelectQuote Inc. et al., after the U.S. Department of Justice (DOJ) intervened in a whistleblower lawsuit alleging deceptive Medicare Advantage sales practices.
- The lawsuit, covering investors who purchased SelectQuote stock between September 9, 2020, and May 1, 2025, alleges the company misled the market about its business model and regulatory exposure.
- Core allegations include steering customers toward plans offering the highest commissions, accepting illegal kickbacks, and violating federal statutes, with the DOJ claiming improper payments and discrimination against less profitable customers from 2016 through at least 2021.
- The federal action led to a 19% drop in SelectQuote’s share price on May 1, 2025, and shares have declined more than 40% over the past six months due to investor concern.
Oct 8, 2025, 10:37 PM
SelectQuote faces class action lawsuit following DOJ False Claims Act complaint
SLQT
Legal Proceedings
- A class action lawsuit has been filed against SelectQuote, Inc. (NYSE:SLQT) on behalf of investors who purchased or acquired securities between September 9, 2020, and May 1, 2025.
- Investors have until October 10, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- The lawsuit stems from a U.S. Department of Justice (DOJ) False Claims Act complaint filed on May 1, 2025, which alleged SelectQuote received "tens of millions of dollars" in "illegal kickbacks" from health insurance companies between 2016 and at least 2021.
- The DOJ claimed SelectQuote directed Medicare beneficiaries to plans offered by insurers that paid the most money, rather than providing unbiased coverage comparisons.
- Following this news on May 1, 2025, SelectQuote’s stock price fell $0.61, or 19.2%, to close at $2.56 per share.
Oct 8, 2025, 7:18 PM
SelectQuote Faces Federal Securities Class Action and DOJ False Claims Act Complaint
SLQT
Legal Proceedings
- Faruqi & Faruqi, LLP is investigating potential claims against SelectQuote, Inc. (NYSE:SLQT) for alleged violations of federal securities laws.
- The complaint alleges that SelectQuote directed Medicare beneficiaries to plans that best compensated the company, did not provide unbiased comparison shopping, and received illegal kickbacks.
- On May 1, 2025, the U.S. Department of Justice (DOJ) filed a False Claims Act complaint against SelectQuote, alleging "tens of millions of dollars" in "illegal kickbacks" from 2016 through at least 2021.
- Following the DOJ news, SelectQuote's stock price fell $0.61, or 19.2%, to close at $2.56 per share on May 1, 2025.
- The deadline for investors who suffered losses between September 9, 2020, and May 1, 2025, to seek the role of lead plaintiff in the federal securities class action is October 10, 2025.
Oct 8, 2025, 1:35 PM
SelectQuote Faces Investor Lawsuit Following DOJ Intervention in Sales Probe
SLQT
Legal Proceedings
Financial Restatement
- SelectQuote Inc. (SLQT) is facing a securities class-action lawsuit after the U.S. Department of Justice (DOJ) intervened in a whistleblower lawsuit alleging deceptive sales practices.
- The lawsuit, Pahlkotter v. SelectQuote Inc. et al., covers investors who purchased stock between September 9, 2020, and May 1, 2025, with a lead plaintiff deadline of October 10, 2025.
- Allegations include SelectQuote steering customers towards plans with the highest commissions, accepting illegal kickbacks, and violating federal statutes, with the DOJ alleging tens of millions in improper payments from 2016 through at least 2021.
- SelectQuote's share price dropped 19% on May 1, 2025, following the DOJ's involvement, and has declined more than 40% over the past six months due to investor concerns.
Oct 7, 2025, 11:33 PM
Quarterly earnings call transcripts for SelectQuote.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more